CN113271977A - 使用艾日布林和选择性cdk4/6抑制剂组合治疗癌症的治疗方案 - Google Patents

使用艾日布林和选择性cdk4/6抑制剂组合治疗癌症的治疗方案 Download PDF

Info

Publication number
CN113271977A
CN113271977A CN201980088426.8A CN201980088426A CN113271977A CN 113271977 A CN113271977 A CN 113271977A CN 201980088426 A CN201980088426 A CN 201980088426A CN 113271977 A CN113271977 A CN 113271977A
Authority
CN
China
Prior art keywords
cancer
eribulin
cdk4
inhibitor
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980088426.8A
Other languages
English (en)
Chinese (zh)
Inventor
J·A·索伦蒂诺
P·J·罗伯茨
J·C·斯特鲁姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
G1 Therapeutics Inc
Original Assignee
G1 Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G1 Therapeutics Inc filed Critical G1 Therapeutics Inc
Publication of CN113271977A publication Critical patent/CN113271977A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201980088426.8A 2018-11-09 2019-11-12 使用艾日布林和选择性cdk4/6抑制剂组合治疗癌症的治疗方案 Pending CN113271977A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862758388P 2018-11-09 2018-11-09
US62/758,388 2018-11-09
PCT/US2019/061010 WO2020097625A1 (en) 2018-11-09 2019-11-12 Therapeutic regimens for treatment of cancer using eribulin and selective cdk4/6 inhibitor combinations

Publications (1)

Publication Number Publication Date
CN113271977A true CN113271977A (zh) 2021-08-17

Family

ID=70612537

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980088426.8A Pending CN113271977A (zh) 2018-11-09 2019-11-12 使用艾日布林和选择性cdk4/6抑制剂组合治疗癌症的治疗方案

Country Status (5)

Country Link
US (1) US20210267986A1 (enExample)
EP (1) EP3877422A4 (enExample)
JP (1) JP2022506829A (enExample)
CN (1) CN113271977A (enExample)
WO (1) WO2020097625A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190092478A (ko) 2016-12-05 2019-08-07 쥐원 쎄라퓨틱스, 인크. 화학요법 레지멘 동안의 면역 반응의 보존
MX2019008158A (es) 2017-01-06 2019-12-09 G1 Therapeutics Inc Terapia de combinacion para el tratamiento del cancer.
KR20230012547A (ko) 2020-05-19 2023-01-26 쥐원 쎄라퓨틱스, 인크. 의학적 장애의 치료를 위한 시클린-의존성 키나제 억제 화합물
WO2022087018A1 (en) * 2020-10-19 2022-04-28 G1 Therapeutics, Inc. Improved fluorouracil-based multi-agent chemotherapy for treatment of metastatic colorectal cancer
CN114748480B (zh) * 2021-01-08 2023-10-20 轩竹生物科技股份有限公司 一种预防和/或治疗癌症的药物组合物

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103429243A (zh) * 2010-10-25 2013-12-04 G1治疗公司 Cdk抑制剂
WO2014087230A1 (en) * 2012-12-04 2014-06-12 Eisai R&D Management Co., Ltd. Use of eribulin in the treatment of breast cancer
US20150297606A1 (en) * 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic Lactams for Use in the Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
CN105407889A (zh) * 2013-03-15 2016-03-16 G1治疗公司 针对Rb阳性异常细胞增殖的HSPC节制性治疗
US20160220569A1 (en) * 2015-02-03 2016-08-04 G1 Therapeutics, Inc. CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy
CN106029070A (zh) * 2014-03-03 2016-10-12 卫材R&D管理有限公司 艾日布林和mTOR抑制剂作为治疗癌症的联合疗法的用途
CN106413705A (zh) * 2014-05-28 2017-02-15 卫材R&D管理有限公司 艾日布林在治疗癌症中的用途
US20170182043A1 (en) * 2014-09-12 2017-06-29 G1 Therapeutics, Inc. Anti-Neoplastic Combinations and Dosing Regimens using CDK4/6 Inhibitor Compounds to Treat RB-Positive Tumors
WO2018005533A1 (en) * 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Antiproliferative pyrimidine-based compounds
WO2018106729A1 (en) * 2016-12-05 2018-06-14 G1 Therapeutics, Inc. Preservation of immune response during chemotherapy regimens
WO2018129387A1 (en) * 2017-01-06 2018-07-12 G1 Therapeutics, Inc. Combination therapy for the treatment of cancer
WO2019017497A1 (en) * 2017-07-21 2019-01-24 Eisai R&D Management Co., Ltd. USE OF CYCLIN-DEPENDENT KINASE ERIBULINE AND INHIBITORS IN THE TREATMENT OF CANCER

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160166536A1 (en) * 2014-12-12 2016-06-16 Northwestern University Combination therapy for the treatment of cancer
JP2019524748A (ja) * 2016-07-20 2019-09-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 がんの治療におけるエリブリン及びヒストンデアセチラーゼ阻害剤の使用
CN110891588A (zh) * 2017-05-11 2020-03-17 艾瑞朗医疗公司 拟肽大环化合物及其用途

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103429243A (zh) * 2010-10-25 2013-12-04 G1治疗公司 Cdk抑制剂
WO2014087230A1 (en) * 2012-12-04 2014-06-12 Eisai R&D Management Co., Ltd. Use of eribulin in the treatment of breast cancer
CN105407889A (zh) * 2013-03-15 2016-03-16 G1治疗公司 针对Rb阳性异常细胞增殖的HSPC节制性治疗
CN106029070A (zh) * 2014-03-03 2016-10-12 卫材R&D管理有限公司 艾日布林和mTOR抑制剂作为治疗癌症的联合疗法的用途
US20150297607A1 (en) * 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic Lactams for Use in the Protection of Normal Cells During Chemotherapy
US20150297606A1 (en) * 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic Lactams for Use in the Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
CN106413705A (zh) * 2014-05-28 2017-02-15 卫材R&D管理有限公司 艾日布林在治疗癌症中的用途
US20170182043A1 (en) * 2014-09-12 2017-06-29 G1 Therapeutics, Inc. Anti-Neoplastic Combinations and Dosing Regimens using CDK4/6 Inhibitor Compounds to Treat RB-Positive Tumors
US20160220569A1 (en) * 2015-02-03 2016-08-04 G1 Therapeutics, Inc. CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy
WO2018005533A1 (en) * 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Antiproliferative pyrimidine-based compounds
WO2018106729A1 (en) * 2016-12-05 2018-06-14 G1 Therapeutics, Inc. Preservation of immune response during chemotherapy regimens
WO2018129387A1 (en) * 2017-01-06 2018-07-12 G1 Therapeutics, Inc. Combination therapy for the treatment of cancer
WO2019017497A1 (en) * 2017-07-21 2019-01-24 Eisai R&D Management Co., Ltd. USE OF CYCLIN-DEPENDENT KINASE ERIBULINE AND INHIBITORS IN THE TREATMENT OF CANCER

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
JOHN E. BISI1等: ""Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression"", 《MOLECULAR CANCER THERAPEUTICS》 *
KENICHI NOMOTO等: ""Synergistic anticancer activity of eribulin plus palbociclib inpatient-dervied xenograft (PDX) models of ER+/Her2- human breast cancer"", 《MOL CANCER THER》 *
KENICHI NOMOTO等: "Abstract B191: Synergistic anticancer activity of eribulin plus palbociclib in patient-derived xenograft (PDX) models of ER+/Her2- human breast cancer" *
P.J. ROBERTS等: ""Trilaciclib (G1T28), a CDK4/6 inhibitor, enhances the efficacy of combination chemotherapy and immune checkpoint inhibitor treatment in preclinical models"", 《ANNALS OF ONCOLOGY》 *
P.J. ROBERTS等: "Trilaciclib (G1T28), a CDK4/6 inhibitor, enhances the efficacy of combination chemotherapy and immune checkpoint inhibitor treatment in preclinical models" *
SHREYAS S. RAO等: ""Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer"", 《ONCOTARGET》 *
TONGZHENG LIU等: ""CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1"" *

Also Published As

Publication number Publication date
WO2020097625A1 (en) 2020-05-14
EP3877422A4 (en) 2022-08-24
US20210267986A1 (en) 2021-09-02
JP2022506829A (ja) 2022-01-17
EP3877422A1 (en) 2021-09-15

Similar Documents

Publication Publication Date Title
CN113271977A (zh) 使用艾日布林和选择性cdk4/6抑制剂组合治疗癌症的治疗方案
AU2016202621B2 (en) Combination of inotuzumab ozogamicin and torisel for the treatment of cancer
US9254299B2 (en) Administration of hypoxia activated prodrugs in combination with Chk1 inhibitors for treating cancer
JP6525474B2 (ja) オーロラキナーゼ阻害剤と抗ｃｄ３０抗体の併用
CN110035759A (zh) 化疗方案期间免疫反应的保持
JP2024072291A (ja) 同種抗体により駆動される慢性移植片対宿主病を処置及び予防する方法
JP2013533257A (ja) 血液癌の治療法
US20160220569A1 (en) CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy
CN107106685A (zh) 协同澳瑞他汀组合
JP7717065B2 (ja) Ａｌｋ２阻害剤及びｊａｋ２阻害剤を含む併用療法
CN112867512A (zh) 联合疗法
JP7266030B2 (ja) リンパ球悪性疾患を治療するための方法
KR20210002015A (ko) Flt3 저해제 및 화학치료제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물
US20150231198A1 (en) Combination therapy for hematological malignancies
US20120308562A1 (en) Methods of treating mesothelioma with a pi3k inhibitor compound
Gupta et al. Palbociclib: A breakthrough in breast carcinoma in women
KR20140062143A (ko) Pi3k 베타 억제제, 및 mek 및 raf 억제제를 포함하는 mapk 경로 억제제를 사용하여 암을 치료하기 위한 조성물 및 방법
JP2016520665A (ja) Ｍｐｓ−１キナーゼ阻害剤および有糸分裂阻害剤を含む、癌の治療のための組合わせ
CN112891353B (zh) 药物组合及其用途
HK40059017A (en) Therapeutic regimens for treatment of cancer using eribulin and selective cdk4/6 inhibitor combinations
JP2020528052A (ja) がん治療におけるエリブリン及びサイクリン依存的キナーゼ阻害剤の使用
US20220016118A1 (en) Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof
WO2023192291A2 (en) Indolium compounds for treating cancer
CN119816307A (zh) 包含flt3抑制剂的癌症组合疗法
Dhingra et al. Expanding horizons in the treatment of mantle cell lymphoma: Ibrutinib a novel BTK-targeting inhibitor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40059017

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210817

WD01 Invention patent application deemed withdrawn after publication